(S)-(+)-Mecamylamine (TC-5214): A Neuronal Nicotinic Receptor Modulator Enters Phase III Trials as an Adjunct Treatment for Major Depressive Disorder (MDD)

Eitemau Tebyg

• TC‐5214 (S‐(+)‐Mecamylamine): A Neuronal Nicotinic Receptor Modulator with Antidepressant Activity
  gan: Lippiello, Patrick M., et al.
  Cyhoeddwyd: (2008)
• Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)
  gan: Zajecka, John M, et al.
  Cyhoeddwyd: (2019)
• Translating laboratory discovery to the clinic: From nicotine and mecamylamine to tourettes, depression, and beyond
  gan: Sanberg, Paul R., et al.
  Cyhoeddwyd: (2012)
• The neurocognitive profile of post‐traumatic stress disorder (PTSD), major depressive disorder (MDD), and PTSD with comorbid MDD
  gan: Koopowitz, Sheri‐Michelle, et al.
  Cyhoeddwyd: (2021)
• The process of major depressive disorder (MDD) in women referred to the health centers
  gan: Rahmati-Khameneh, Souraj, et al.
  Cyhoeddwyd: (2011)